The Secrets of Securing a Senior Scientist Role in an Industry
The Secrets of Securing a Senior Scientist Role in an Industry
Nathalie Fuentes shared her experience of landing a unicorn position in a pharmaceutical company after a postdoctoral fellowship.
Nathalie Fuentes shared her experience of landing a unicorn position in a pharmaceutical company after a postdoctoral fellowship.
Big Pharma
What’s the Evidence for Fluvoxamine in COVID-19?
Catherine Offord | May 20, 2022 | 7 min read
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019 | 2 min read
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
FDA Commissioner Scott Gottlieb Announces Resignation
Jef Akst | Mar 5, 2019 | 1 min read
Gottlieb will step down after two years at the helm of the US Food and Drug Administration to spend more time with his family.
Cochrane Collaboration Expels Cofounder, Prompts Resignations
Catherine Offord | Sep 18, 2018 | 3 min read
Physician Peter Gøtzsche, a board member of the organization, has been an outspoken critic of certain vaccines and of the pharma industry in general.
NIH Won’t Use Industry Money for Opioid Research Initiative
Shawna Williams | Apr 19, 2018 | 1 min read
The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 22, 2018 | 2 min read
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
Dengue Vaccine Program Halted Over Safety Issues
Shawna Williams | Dec 5, 2017 | 2 min read
The drug may worsen future infections for people who haven't already been exposed to the virus.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017 | 4 min read
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion
Joshua A. Krisch | Jan 9, 2017 | 1 min read
The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.
TS Picks: August 9, 2016
Bob Grant | Aug 9, 2016 | 2 min read
Gene therapy money-back guarantee; the brain benefits from bilingualism; Q&A with a science watchdog
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 17, 2016 | 2 min read
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Bayer Enters CRISPR Field
Karen Zusi | Dec 22, 2015 | 1 min read
The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.
Pfizer and Allergan to Merge
Bob Grant | Nov 23, 2015 | 1 min read
The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.
Shire Buys Rare Disease Drug Developer
Tracy Vence | Nov 2, 2015 | 1 min read
The Irish drugmaker is set to acquire the Massachusetts-based Dyax in a $5.9 billion deal.
Hearing Help
Kate Yandell | Sep 1, 2015 | 10+ min read
For decades, the only remedies for hearing loss were devices such as hearing aids or cochlear implants. Now, the first pharmaceutical treatments may be on the way.
Legionnaires’ Bacteria at GSK
Jef Akst | Aug 14, 2015 | 1 min read
GlaxoSmithKline temporarily shuts down a manufacturing plant in North Carolina after Legionella bacteria are detected in two external cooling towers.
Teva Buys Allergan Generics for $40.5 Billion
Tracy Vence | Jul 27, 2015 | 2 min read
Meanwhile, Allergan acquires drug developer Naurex in a $560 million deal.
AbbVie Wins Bidding War for Cancer Drugmaker
Bob Grant | Mar 5, 2015 | 1 min read
The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.
Pfizer to Acquire Hospira
Bob Grant | Feb 5, 2015 | 1 min read
The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.